All

API

FDF

Price

Services

Excipients

Enquiries

Find

Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace

Market Place

Post Enquiry

Grow Your Pharma Business Digitally

pipeline-prospector-insert

X

Find Clinical Drug Pipeline Developments & Deals for TRC253

All Data

Filters

refresh

×

FILTER DATA :

Therapeutic Area

Study Phase

Country

News Type

Company

refresh

Companies By Therapeutic Area

Development Status

Janssen Pharmaceutical

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

IFT Annual Expo

Participation Not Confirmed

Update your events

TRACON Retains Global Rights to TRC253 Following Completion of a Phase 1/2 Trial

Contact the Supplier

Lead Product(s): TRC253

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: TRACON Pharmaceuticals

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement April 24, 2020

Details:

The announcement came in the sense of Janssen Pharma's decision not to exercise their option to re-acquire TRC253's global rights after a analysis of the data in Phase 2.